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Objective: To determine the use of oral anti-inﬂammatory drugs in the year before and the 2 years after
primary total hip (THR) or knee (TKR) replacement, and whether this varies according to Body mass
Index (BMI).
Design: 28,068 THR’s and 24,364 TKR’s, with ﬁve matched controls per case were identiﬁed from the
General Practitioner Research Database. Anti-inﬂammatory usage was categorized into “zero coverage” e
no prescribed anti-inﬂammatory medication and “>80% coverage” e prescribed anti-inﬂammatory
medication for greater than 80% of the days in the year. Secondary subset analysis was performed
according to BMI.
Results: 1 year post-surgery the proportion of cases on >80% coverage reduced from 21% (95%conﬁdence
interval (CI): 20e22%) to 8% (95%CI: 7e10%) for THR and 21% (95%CI: 20e22%) to 13% (95%CI: 11e14%) for
TKR, with no ongoing reduction at 2 years. Zero coverage increased at one and both time points. The
proportion of THR’s on >80% coverage increased with BMI pre-op. The magnitude in reduction post-op
was similar across all BMI groups. The proportion of TKR’s on >80% coverage pre-op was greatest in
extreme BMI categories. The magnitude in reduction post-op was similar across all BMI groups.
Conclusion: THR/TKR’s reduce the need for anti-inﬂammatory medication with most beneﬁt observed in
the ﬁrst post-operative year. Increasing BMI affects anti-inﬂammatory use both in the general population
and those undergoing THR/TKR surgery but without strong evidence of a detrimental effect on the
beneﬁts of pain relief.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The number of primary total joint replacements being
performed per annum in the UK is currently rising and has been
predicted to continue to increase by as much as 50% by 20261,2.
This has been attributed to the combination of an ageing pop-
ulation and a greater willingness of surgeons to operate on younger
patients. Obesity has also been shown to be an independent factor: Nigel K Arden, University
emiology Resource Centre,
)-2380-777 624; Fax: 44-(0)-
.
s Research Society International. Pcontributing to the risk of developing hip and knee osteoarthritis
(OA)3e7. The prevalence of obesity amongst adults has increased
from 13% in 1993 to 24% in 2006 for men and from 16% to 24% for
women. Furthermore it has been predicted that by 2015, 36% of
women and 28% of men aged between 21 and 60 will be obese, and
by 2025 to further rise to 56% and 47% respectively (www.foresight.
gov.uk)8. These increases therefore are likely to play an important
role in the predicted rise in the number of lower limb arthroplasty
procedures performed in the subsequent decades. There is con-
ﬂicting evidence on the role of obesity in determining the outcome
of lower limb joint replacements. Studies assessing the outcome of
hip replacement have shown no statistically signiﬁcant difference
in scores between obese and non-obese groups with similar
improvements in function and patient satisfaction9e11. Followingublished by Elsevier Ltd. All rights reserved.
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with studies showing both similar12e14 but also inferior15 outcome
in the obese compared with the non-obese patient.
Historically total hip (THRs) and knee (TKRs) replacements have
been amongst the most successful and reliable orthopaedic
procedures for pain relief and improvement on quality of life, with
greater than 90% success rate at 10 years16. Success in these studies
have been largely based on prosthesis survival, however there is
now a greater focus on patient symptoms in assessing outcome
after joint replacement17. A recent study utilising data from the
National Joint Registry reported 80% self reported patient satisfac-
tion following TKR at 12 months18. Following THR patient satis-
faction has been reported to be higher and closer to 90%19. Oral
anti-inﬂammatory drugs (including traditional NSAIDs and cox-2
speciﬁc inhibitors) remain one of the fundamental treatment
modalities in hip and knee OA20 and residual post-operative pain
and have been demonstrated to be used by approximately 45% of
patients awaiting surgery21,22 but have a number of well docu-
mented adverse gastrointestinal and cardiovascular side effects,
particularly in the elderly23. These side effects cause considerable
morbidity and occasional mortality and incur substantial costs to
healthcare providers and purchasers.
The primary aim of this study was to use data from the General
Practice Research Database (GPRD), to determine the use of oral
anti-inﬂammatory drugs use in the year before and the 2 years after
primary THR or TKR replacement, as a surrogate marker of effective
pain relief following each procedure, and compare this to matched
controls. The secondary aim was to determine the effect of Body
Mass Index (BMI) on the use of these agents.
Method
Patient selection
We used data obtained from the GPRD. The GPRD comprises the
entire computerized medical records of a sample of patients
attending general practitioners (GPs) in the UK covering a pop-
ulation of 6.5 million patients from 433 contributing practices
chosen to be representative of the wider UK population. GPs in the
UK play a key role in the delivery of healthcare by providing
primary care and referral to specialist hospital services. Patients are
registered with one practice that stores medical information from
primary care and hospital attendances. The GPRD is administered
by the Medicines and Healthcare products Regulatory Agency
(MHRA).
The GPRD records contain all clinical and referral events in both
primary and secondary care in addition to comprehensive demo-
graphic information, prescription data, and hospital admissions.
Data is stored using OXMIS and Read codes for diseases that are
cross-referenced to the International Classiﬁcation of Diseases
(ICD-9). Only practices that pass quality control are used as part of
the GPRD database. Deleting or encoding personal and clinic
identiﬁers ensures the conﬁdentiality of information in the GPRD.
We identiﬁed all patients in the database with a medical diag-
nosis code for hip or knee arthroplasty from 1991 to the end of
2006. Read/OXMIS codes were used to identify primary THRs and
TKRs. Patients were included in the analysis if aged 18 or over at the
time of the replacement. For each THR/TKR subject we selected ﬁve
non-THR/TKR subjects that were matched for age (nearest integer
age), sex and GP practice. The non-THR/TKR subjects were given an
index date corresponding to the operation date of their matched
case.
The GPRD Product dictionary was searched and all Read/OXMIS
codes for oral traditional NSAIDs, cox-2 selective and cox-2
speciﬁc drugs were obtained. For this analysis all identiﬁed codeswere grouped together and categorized as oral anti-inﬂammatory
drugs. The individual prescriptions in the years before and the 2
years following surgery were extracted. Using the formulation of
drug, dose, number of tablets prescribed and instructions, we
calculated the number of days per year that the patient had access
to oral anti-inﬂammatory drugs: the medication possession ratio
(MPR).
The MPR for both THR/TKR subjects and non-THR/TKR subjects
was non-parametric and could not be transformed to a parametric
distribution. Oral anti-inﬂammatory usage was therefore analyzed
as two categories: (1) “zero coverage” e patients who were not
prescribed any anti-inﬂammatory medication; (2) “greater than
80% coverage” e patients who were prescribed anti-inﬂammatory
medication for greater than 80% of the days in the year23,24.
Participant demographics including age, gender, number of
comorbid conditions (categorized into none, one or two or more
conditions), BMI categorized according to the World Health Orga-
nisation (WHO) classiﬁcation, smoking status, alcohol consumption
and underlying diagnosis (OA, rheumatoid arthritis and other) were
collated. Comorbid conditions were deﬁned according to systems.
These included Cardiovascular (Hypertension, Myocardial Infarc-
tion, Cerebrovascular Accident and Hyperlipidaemia), Respiratory
(Asthma, Bronchitis, COPD, Emphysema), Gastrointestinal (Crohn’s,
Ulcerative Colitis/colitis, Coeliac), Renal disease and General (Dia-
betes, malignancy and fractures).Analysis
The proportions of THR and TKR subjects and non-THR and TKR
subjects, on either zero or 80% coverage, were identiﬁed over three
separate time points (1 year before surgery; 1 year and 2 years post-
surgery). Further analyses were performed by stratifying the data
according to BMI status. BMI categories were chosen according to
the WHO classiﬁcation (<18.5: underweight, 18.5e25: normal,
25e30: overweight, >30: obese). Further comparison was also
made between the obese (30e34.9) and a severely obese category
(>35). Only pre-operative BMI measurements recorded within 5
years of surgery were used. BMI values less than 15 or greater than
50 kg/m2 were considered likely to be invalid and were therefore
not used in the analysis. Odds ratios (ORs) were calculated for zero
and >80% anti-inﬂammatory use in THR/TKR subjects compared to
non-THR/TKR subjects, over the three time points, for both the
whole cohort and the BMI subgroups, and adjusted for age, gender
and comorbid conditions as potential confounding variables. An
unmatched analysis, breaking the original matching of THR/TKR
subjects and non-THR/TKR subjects before stratifying both THR/
TKR subjects and non-THR/TKR subjects by BMI, using uncondi-
tional logistic regression was used to obtain these ORs, after ﬁrst
verifying that such an analysis would not substantially alter the
matching balance between THR/TKR subjects and non-THR/TKR
subjects within the BMI subgroups.Results
Patient demographics (Table I)
28,068 patients who had undergone a THR and 24,364 patients
who had undergone a TKR were identiﬁed from the database. The
average age was similar in both THR and TKR cohorts but there was
a greater proportion of female subjects within the TKR group. For
both the THR and TKR cohorts, there was an increase in the number
of comorbid medical conditions compared to non-THR/TKR cohorts
(THR: P< 0.0001; TKR: P< 0.0001). In those patients where the
indication for surgery/aetiology could be accurately ascertained
Table I
Clinical and demographic characteristics
THR TKR
Cases Controls Cases Controls
N¼ 28068 N¼ 140329 N¼ 24364 N¼ 121809
Age (mean, SD) 69.3 (11.1) 69.3 (11.1) 70.3 (9.6) 70.3 (9.6)
Gender (% \) 62.6 62.6 59.4 59.4
BMIz,x (mean, SD) 27.4 (4.8) 26.4 (4.8) 29.1 (5.0) 26.4 (4.7)
No. of comorbid conditions (%)
0 36.8 42.9 33.9 41.1
1 37.6 33.6 37.3 33.9
2þ 25.6 23.5 28.8 24.9
Smoking status* (N, %)
Ex-smoker 8202 (30.5%) 36109 (28.2%) 7673 (32.5%) 33211 (29.8%)
Non-smoker 15167 (56.4%) 69815 (54.5%) 13504 (57.3%) 59073 (53.0%)
Smoker 3503 (13.0%) 22066 (17.2%) 2403 (10.2%) 19233 (17.3%)
Alcohol consumptiony (N, %)
Ex-drinker 1572 (6.4%) 7395 (6.4%) 1619 (7.4%) 6708 (6.6%)
Non-drinker 3541 (14.4%) 19626 (17.0%) 3421 (15.7%) 17303 (17.1%)
Drinker 19479 (79.2%) 88708 (76.7%) 16766 (76.9%) 77074 (76.3%)
Indications for surgery k(%)
RA 2.4% 3.5%
OA 94.5% 91.5%
Others 3.1% 5.0%
* Smoking status ascertained in 92.2% of subjects.
y Alcohol consumption ascertained in 83.7% of subjects.
z Pre-operative BMI recorded within 5 years of surgery was available for 54.1% of subjects (cases 58.6%, controls 53.4%).
x BMI values below 15 and above 50 were considered suspect and were treated as missing values.
k In subjects where indication could be ascertained (THRs 78.9%; TKRs 85.5%).
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3e5% performed for Rheumatoid Arthritis (Table I).Anti-inﬂammatory use pre- and post-surgery
Both THR and TKR subjects had similarly high rates of anti-
inﬂammatory use in the year before operation with 21% having an
MPR of at least 80%, which was signiﬁcantly greater than in their
matched non-THR/TKR subjects (2.1% and 2.2% respectively). Of
interest was that 39% of THRs and 39% of TKRs had no anti-
inﬂammatory prescriptions in the year before surgery compared to
83% and 82% in the respective non-THR/TKR groups.
At 1 year post-surgery the proportion with greater than 80%
coverage decreased for both THR and TKR cohorts. However the
absolute reduction was greater in patients who had hip
replacements (13% THR’s: 21% pre-op to 8% 1 year post-op) than
those who had knee replacements (8% TKR’s: 21% pre-op to 13% 1
year post-op). There was no further reduction observed in the
>80% cohort at 2 years [Fig. 1(a)]. The odds of being on >80%
coverage for THR/TKR subjects against non-THR/TKR subjects
conﬁrmed these results, both before and after adjusting for age,
gender and number of comorbid conditions (THR pre-op OR:
12.28, 95%conﬁdence interval (CI): 11.72,12.87; 1 year post-op OR
4.06, 95%CI: 3.84,4.30. TKR pre-op OR 11.20, 95%CI: 10.66,11.77; 1
year post-op OR 6.17, 95%CI 5.85,6.51). The proportion of patients
with zero coverage increased in the ﬁrst year following surgery
but also continued to rise at 2 years. The absolute increase in
patients on zero coverage was more marked in those who had
undergone THR (13.2% in ﬁrst year post-op, 13.8% in second year
post-op) than TKR (6.7% in ﬁrst year post-op, 12.1% in second year
post-op).
In the matched non-THR/TKR group the proportion of THR/
TKR subjects on zero or >80% was similar in both THR and TKR
cohorts and remained unchanged over the subsequent time
periods (non-THR subjects: 2.1%, 2.2%, 2.2% at pre-, 1 year and 2years post-op). Non-TKR subjects: 2.2%, 2.3%, 2.3% at pre-, 1 year
and 2 years post-op [Fig. 1(a and b)].BMI analysis
Non-THR/TKR subjects
The percentage of non-THR/TKR subjects on >80% coverage,
representing background anti-inﬂammatory usage in patients
without hip or knee degenerative joint disease increased with BMI
(non-THR subjects: 1.5%, 1.7%, 2.1%, 3.2%, 4.9%). Non-TKR subjects:
1.7%, 1.7%, 2.4%, 3.6%, 5.0%.
THR (>80% coverage)
At 1 year prior to THR surgery the proportion of THR subjects on
>80% anti-inﬂammatory coverage increased in a dose response
fashion with BMI (14%, 18%, 21%, 27%, 30%). 1 year post-operatively
there was a reduction in>80% anti-inﬂammatory use across all BMI
groups; however the reduction was less marked in the under-
weight category. In the remaining groups (normal, overweight,
obese and severely obese) an increasing BMI did not have a dele-
terious effect on the degree of reduction in anti-inﬂammatory use
seen at 1 year post-operatively; however obese patients still had
the highest use. Between 1 and 2 years post-operatively there was
no further reduction in anti-inﬂammatory use for normal, over-
weight and obese patients [Fig. 2(a)].
When compared to non-THR subjects of the same BMI group,
THR patients had between a 9.6- and 12.5-fold increased odds of
having an MPR of 80% anti-inﬂammatory use. The reduction in ORs
between pre-op and 1 year post-op was less in the underweight
group but similar in the remaining groups (see Table II).
TKR (>80% coverage)
At 1 year prior to surgery the greatest proportion of patients on
>80% anti-inﬂammatory use were in the extreme BMI groups
(underweight: 23%, obese: 23%, severely obese: 24%), contrary to the
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Fig. 1. a. Proportion of cases on >80% anti-inﬂammatory coverage the year before and at 1 and 2 years following THR or TKR surgery (with 95% CIs). b. Proportion of cases on 0%
anti-inﬂammatory coverage the year before and at 1 and 2 years following THR or TKR surgery (with 95% CIs).
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Fig. 2. a. Proportion of cases according to BMI on >80% anti-inﬂammatory coverage the year before and at 1 and 2 years following THR surgery (with 95% CIs). b. Proportion of cases
according to BMI on >80% anti-inﬂammatory coverage the year before and at 1 and 2 years following TKR surgery (with 95% CIs).
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with increasing BMI. At 1 year there was a fall in >80% anti-inﬂam-
matory use with similar magnitude across all BMI groups [Fig. 2(b)].
When compared to non-TKR subjects of the same BMI group,
the ORs for>80% use in the year before surgerywere greatest in the
underweight group and gradually decreased as BMI increased. The
reduction in ORs from before to a year after surgery was smaller
than that seen for THR and was more consistent across BMI groups
with the exception of the underweight group (see Table II).
TKR/THR (zero coverage)
For both THRs and TKRs the change of proportions and ORs
according to BMI were similar to those observed with >80%
coverage from pre- to 1 year post-op, with an increase in those onzero coverage. However from 1 to 2 years there was an ongoing
increase in the proportions on zero coverage for both THR and TKR
in all BMI groups, along with a reciprocal drop in ORs of non-THR/
TKR subjects vs THR/TKR subjects.
Change in BMI over time
For both THR/TKR subjects and non-THR/TKR subjects there was
no reduction in mean BMI from pre- to 1 and 2 years post-surgery
(THR/TKR subjects: Mean BMI 29.3, 29.7, 29.8. N¼ 5589); (non-
THR/TKR subjects 29.4, 29.4, 29.4. N¼ 22490). There was also no
reduction in BMI over time either by gender (Female mean BMI:
29.5, 30.0, 30.1; N¼ 3218. Male mean BMI: 29.0, 29.4, 29.5;
N¼ 2371), or by operation (THR subjects mean BMI: 28.4, 29.0,
29.1; N¼ 2713. TKR subjects mean BMI: 30.0, 30.4, 30.6; N¼ 2876).
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Summary of results
This study demonstrates that total hip and knee arthroplasty
procedures reduce the patient’s need for anti-inﬂammatory drugs
at 1 and 2 years post-operatively. This beneﬁt appears dependent
on the site of surgery with the greater reductions seen following
THR than TKR. The majority of the reduction or regular use occurs
within the ﬁrst year of surgery, although there is still an increase in
the number of patients not using any anti-inﬂammatory drugs in
the second year. At no point does the use of anti-inﬂammatory
drugs approach those of the matched non-THR/TKR subjects.
Increasing BMI increases the use of anti-inﬂammatory drugs in
both the hip and knee cohorts in the pre-operative and post-
operative period; however this does not appear to have a detri-
mental effect on the relative reduction in anti-inﬂammatory use in
the post-operative period when compared to non-THR/TKR
subjects of the same BMI.
Following arthroplasty surgery prosthetic survival has tradi-
tionally been the primary measurement of outcome. However
recent emphasis has been directed towards patient related
outcome measures (PROMs) as a more important and relevant
method of outcome analysis. This study has utilised the GPRD to
establish the anti-inﬂammatory usage, as a surrogate marker of
pain relief and PROM before and after THR and TKR surgery. The
measurement of anti-inﬂammatory usage also has implications
regarding the potential and well documented side effects of their
long term usage. We also however acknowledge that there are
limitations with using anti-inﬂammatory usage as an outcome
measure including confounding variables such as the purchasing of
over the counter (OTC) anti-inﬂammatory medications, those who
have a contraindication to taking anti-inﬂammatory medication,
different prescribing patterns by GPs and those who are not helped
by anti-inﬂammatory drugs25, and therefore must be considered in
interpretation of the data.
Previous comparisons in outcome following THR and TKR have
suggested that both procedures are comparable in terms of both
cost-effectiveness26 and reduction in pain and disability scores27. In
this study both THR and TKR surgery was beneﬁcial in reducing the
anti-inﬂammatory requirements of patients. Both THR and TKR
patients had similar requirements pre-operatively but post-oper-
atively a greater reduction was seen following THR. The majority of
this beneﬁt was shown to occur within the ﬁrst year of surgery.
However there was evidence on ongoing improvement, albeit to
a lesser degree, between years 1 and 2, which were similar in
magnitude for both THR and TKR subjects. The introduction of
PROMs has recommended determining outcome at 6 months post-
operatively17. This study has demonstrated that outcome continues
to improve after this time point and suggests that assessments of
PROMs following either THR or TKR surgery, could provide addi-
tional information if continued beyond 6 months. Denham et al.
demonstrated very similar ﬁndings in a study looking at various
outcomes measures, including pain relief, following THR. They
found a large improvement in pain relief up to 2 years post-oper-
atively but after 4 years there was a gradual, sustained
deterioration28.
The secondary aim of the studywas to establish the effect of BMI
on anti-inﬂammatory use in the THR/TKR subjects before and after
surgery along with the non-THR/TKR subjects. BMI was shown to
have an effect not only on patients with degenerative joint disease
but also those without as demonstrated in the non-THR/TKR group
by an increase in anti-inﬂammatory background use with BMI. This
consequently resulted in the differing observed patterns of the
degree of reduction of anti-inﬂammatory use over time between
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relative odds of THR/TKR subjects being on anti-inﬂammatory
drugs over non-THR/TKR subjects.
In the THR cohort, anti-inﬂammatory use increased with BMI,
however the relative reduction in anti-inﬂammatory use at 1 year
remained very similar for normal, overweight and obese subjects.
The absolute decline in ORs was similar in these three BMI groups,
but was numerically smallest in the obese group. Therefore
although patients were more likely to be taking an anti-inﬂam-
matory following THR as their BMI increased, their relative overall
outcome when compared to a weighted matched subject without
degenerative hip disease were similar. This data supports other
studies which conﬁrm that obesity does not have a detrimental
effect on outcome following THR surgery and that these patients
have as much to gain as non-obese patients12e14. The obese
patients however, always have a greater use of anti-inﬂammatory
drugs and therefore greater potential gastrointestinal and cardio-
vascular complications.
In the TKR cohort, the linear effect of anti-inﬂammatory and BMI
however was not observed, with the underweight group having the
highest proportion and odds of being on >80% anti-inﬂammatory
coverage both pre- and 1 and 2 years post-operatively. However it
should be noted that this group had by far the fewest number of
subjects of all the BMI subgroups as represented by the wider CIs.
Furthermore within this “pathological” BMI range there was
a greater possibility of additional confounding bias through the
exclusion of comorbidities which were either undiagnosed (occult
neoplasms) or not screened for within this study.
In the obese and severely obese groups, the greater background
level of anti-inﬂammatory usage (non-THR/TKR group) resulted in
the lowest OR both pre- and post-operatively. Additionally the
magnitude of the absolute change in OR in those undergoing TKR
surgery though declined with increasing BMI suggesting that the
relative improvement in relieving pain following surgery lessened
as patient weight increased. Pre-operative chronic pain levels and
obesity have been shown to negatively inﬂuence post-operative
outcome scores29. The increased background use of anti-inﬂam-
matory medication seen with increasing BMI therefore could play
an important role in the outcome of TKR surgery, its complications
and of the side effects of anti-inﬂammatory medication.
Longitudinal analysis established the effect of surgery on BMI
over time. Often the pain of degenerative hip or knee disease effects
mobility and functional/activity levels. The inability to lose weight
prior to surgery is often attributed to the deterioration in activity
and therefore it is postulated that relieving pain post-operatively
will allow greater mobility and ability to exercise and reduce
weight. This however was not the case in this study where
following THR or TKR there was no reduction observed in BMI at
both 1 and 2 years post-operatively. Only 10% of all THR/TKR and
non-THR/TKR subjects had data available for BMI measurements
over all three-time periods introducing a possibility of bias. We
therefore explored this issue by comparing demographics of this
subset to the entire cohort with no observed differences between
THR/TKR subjects and THR/TKR subjects. Furthermore, analyses
using patients with only two of the three measurements also
revealed similar results. This therefore represents a valid compar-
ison between THR/TKR subjects and non-THR/TKR subjects but
with limited data it is not possible to generalize these ﬁndings to
the general population without further conﬁrmation from other
studies.
Strength and potential limitations of the study
The efﬁcacy of registries and databases are dependent on the
quality of the data collection. The data imported into the UK GPRDis in a very detailed descriptive and easily interpretable format
allowing precise and accurate interpretation ensuring for this
study, the reliable calculation of MPR’s. The broad inclusion of
many patient population variables also confers a tremendous
advantage in obtaining representative and valid ﬁndings of the
population as a whole. In particular the dataset covers a wide age
range with inclusion of all racial groups and all degrees of comor-
bidity. Increasing comorbidity can often result in patient exclusion
from studies with subsequent selection bias. We do acknowledge
however that there was a limitation with the availability of recor-
ded BMI data within 5 years of surgery. An additional and major
strength of this study is the unique availability of such an extensive
matched control group that has been able to demonstrate across
the UK population the background use of anti-inﬂammatory in
those not suffering from either OA or any inﬂammatory arthrop-
athy. The large control cohort further consolidates the validity of
the ﬁndings within this study.
Although the data on MPR’s is very accurate in determining the
prescription of drugs, it does not inform us as to whether the medi-
cation was taken by the patient. Patients in pain may also purchase
OTC medication. As our cases were matched to controls on age,
gender andpractice, it is likely that the twogroupswill be reasonable
wellmatchedon factorsdeterminingOTCanti-inﬂammatoryuseand
therefore its use if anything would have a conservative bias on any
observed difference in anti-inﬂammatory use post-surgery.
Conclusion
Total hip and knee arthroplasty reduces the patients need for
anti-inﬂammatory medication, with implications regarding the
side effects of their long term use. The majority of the beneﬁt from
reduction in anti-inﬂammatory use is observed by 1 year post-
operatively suggesting that following lower limb arthroplasty
analysis of PROMs should not be made before this time point.
Increasing BMI affects anti-inﬂammatory use in both the general
population as well as those undergoing THR/TKR surgery but
without strong evidence of a detrimental effect on the beneﬁts of
pain relief.
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